Zobrazeno 1 - 10
of 3 121
pro vyhledávání: '"pomalidomide"'
Publikováno v:
Journal of Medical Case Reports, Vol 18, Iss 1, Pp 1-7 (2024)
Abstract Background Central nervous system involvement in chronic lymphocytic leukemia rarely occurs, and there is no standard therapy for central nervous system involvement in chronic lymphocytic leukemia. This article aims to analyze the diagnosis
Externí odkaz:
https://doaj.org/article/0e8c520c2c59473191845d39f219ae92
Autor:
Chieh-Lin Jerry Teng, Su-Peng Yeh, Tsai-Yun Chen, Yu-Chin Hung, Yun-Chu Lin, Sin Syue Li, Ming-Chung Wang, Shang-Yi Huang
Publikováno v:
Hematology, Vol 29, Iss 1 (2024)
Background/purpose The treatment landscape of relapsed/refractory multiple myeloma (RRMM) is rapidly evolving in Taiwan. The present study aimed to assess the treatment patterns among RRMM patients in Taiwan.Methods This retrospective, chart review-b
Externí odkaz:
https://doaj.org/article/9593eb70b29941de9fe5b26697691dd5
Autor:
Yu. E. Ryabukhina, P. A. Zeynalova, F. M. Abbasbeyli, O. L. Timofeeva, T. T. Valiev, N. A. Kupryshina, A. G. Zhukov
Publikováno v:
Онкогематология, Vol 18, Iss 4, Pp 90-103 (2023)
Multiple myeloma is a malignant tumor characterized by the proliferation of clonal plasma cells and currently remains an incurable disease, despite advances in therapy. Resistance and development of double refractoriness represent a significant probl
Externí odkaz:
https://doaj.org/article/2e9274d2ce5440159cbbdfca401a2dad
Publikováno v:
Онкогематология, Vol 18, Iss 4, Pp 51-57 (2023)
Currently, lenalidomide is the only immunomodulatory drug (IMiD) approved for maintenance therapy in patients with newly diagnosed multiple myeloma who have received high-dose chemotherapy and autologous stem cell transplantation (ASCT). The maintena
Externí odkaz:
https://doaj.org/article/bb282cf23e64404083d4a291820e8107
Autor:
Darrell White, Gary J. Schiller, Sumit Madan, Suzanne Lentzsch, Evgeni Chubar, Noa Lavi, Dane R. Van Domelen, Ohad S. Bentur, Muhamed Baljevic
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
ObjectiveTo identify the optimal dose of selinexor in combination with pomalidomide and dexamethasone (SPd).MethodsAn analysis of efficacy and safety of 2 once-weekly selinexor regimens (60 mg and 40 mg) with pomalidomide and dexamethasone (SPd-60 an
Externí odkaz:
https://doaj.org/article/faf3645ed4d642638bc528022e510fa6
Autor:
Xiaoyan Han, Xincheng Jiang, Jingsong He, Gaofeng Zheng, Yaqin Xiong, Yanling Wen, Yang Yang, Donghua He, Qingxiao Chen, Yi Zhao, Yi Li, Wenjun Wu, Zhen Cai
Publikováno v:
Cancer Medicine, Vol 13, Iss 9, Pp n/a-n/a (2024)
Abstract Background Comparative investigations evaluating the efficacy of pomalidomide‐based (Pom‐based) versus daratumumab‐based (Dara‐based) therapies in patients with relapsed/refractory multiple myeloma (RRMM) remain scarce, both in rando
Externí odkaz:
https://doaj.org/article/3479352bf53a4fd7af72907ced4fea07
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
İbrahim Halil Açar, Birol Güvenç
Publikováno v:
Hematology Reports, Vol 15, Iss 3, Pp 465-473 (2023)
Background and Objectives: Relapsed/refractory extramedullary myeloma (RREMM) is an uncommon and aggressive subtype of multiple myeloma defined by plasma cell proliferation outside the bone marrow. Therapeutic options for RREMM are limited, and the p
Externí odkaz:
https://doaj.org/article/1242c5c14f424764ba29bddbc9bce6c3
Autor:
Sergej Semochkin
Publikováno v:
Современная онкология, Vol 25, Iss 2, Pp 159-167 (2023)
Pomalidomide is a third-generation immunomodulatory drug (IMiD) that has taken an important place in the management of relapsed/refractory multiple myeloma (RRMM) including in patients with resistance to lenalidomide (R). Synergism of antitumor activ
Externí odkaz:
https://doaj.org/article/7246ad34b1f3408f88c60925ec1301e1
Autor:
Rao Prabhala, William E. Pierceall, Mehmet Samur, Lakshmi B. Potluri, Kevin Hong, Teresa Peluso, Srikanth Talluri, Angela Wang, Aishwarya Katiki, Sahan D. Vangala, Michael Buonopane, Vaishnavi Bade, Hannah Seah, Arthur Krogman, Sanika Derebail, Mariateresa Fulciniti, Suzan B. Lazo, Paul Richardson, Kenneth Anderson, Jill Corre, Herve Avet-Loiseau, Anjan Thakurta, Nikhil Munshi
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundMultiple Myeloma (MM) patients exhibit dysregulated immune system, which is further weakened by chemotherapeutic agents. While cereblon-modulating agents, such as pomalidomide and lenalidomide, have been found to improve the immune profile,
Externí odkaz:
https://doaj.org/article/ec54f456dc72424aa10934daa1704895